Journal of Urology and Andrology Research (JUAR) is an international, open-access, peer-reviewed journal dedicated to advancing urologic and andrologic care by publishing the highest quality evidence syntheses, clinical research, and methodological studies.
We invite medical residents & fellows, urologists, andrologists, reproductive medicine specialists, systematic reviewers, researchers, and policymakers to submit their work to a journal committed to methodological rigor and clinical relevance. We are dedicated to disseminating innovative research that helps practitioners interpret and apply the best available evidence to improve patient outcomes and healthcare delivery worldwide — with a special focus on the Australasian, Central-Asian, Asia-Pacific, Africa, Middle East regions, and beyong.
We seek submissions that address:
- Prostate cancer screening, diagnosis, and treatment – balancing early detection with overdiagnosis
- Management of benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS)
- Male infertility – diagnostic algorithms, surgical sperm retrieval, and assisted reproductive outcomes
- Erectile dysfunction as a cardiovascular risk marker – evidence for integrated care
- Endourology and stone disease – comparative effectiveness of PCNL, RIRS, and ESWL
- Robotic and minimally invasive surgery in urologic oncology
- Hypogonadism and testosterone replacement therapy – benefits, risks, and evidence gaps
- Urinary incontinence and pelvic floor disorders – non-surgical vs. surgical management
- Reconstructive urology – evidence for urethral stricture and hypospadias repair techniques
- Pediatric urology – evidence-based management of congenital anomalies
- Environmental and occupational impacts on male reproductive health
- Health equity and access to urologic and andrologic services globally
- Ethics of reproductive technologies, informed consent, and surgical innovation
- Implementation of evidence-based guidelines in low-resource settings
CURRENT ISSUE
Volume 1, Issue 1, 2026
Original Article
Journal of Urology and Andrology Research, 1(1), 2026, juar001
ABSTRACT:
Introduction: Peyronie's disease (PD) is characterized by the development of fibrous plaques within the tunica albuginea, leading to penile deformity and significant psychological distress. While various surgical options exist, plaque incision or excision with grafting remains the gold standard for correcting complex or severe curvatures (>60–70°). This review evaluates the clinical outcomes, technical success, and complication rates of various autograft materials.
Historically, dermal grafts were the first autografts used but have fallen out of favor due to high rates of penile shortening (45–70%) and de novo ED (up to 66.7%). Saphenous vein grafts (SVG) demonstrate an initial success rate of ~85.6%, though long-term follow-up indicates a decline in straightness and rising ED rates (22.5%). Tunica albuginea and tunica vaginalis grafts show high technical success (90–100%) with low metabolic demand. More contemporary options, specifically fascia (lata and temporalis) and buccal mucosa grafts (BMG), show superior outcomes. Fascia grafts report technical success rates near 100% with minimal shortening. BMG demonstrates a 94.1% success rate with low de novo ED (0–10%) and rapid tissue integration.
Historically, dermal grafts were the first autografts used but have fallen out of favor due to high rates of penile shortening (45–70%) and de novo ED (up to 66.7%). Saphenous vein grafts (SVG) demonstrate an initial success rate of ~85.6%, though long-term follow-up indicates a decline in straightness and rising ED rates (22.5%). Tunica albuginea and tunica vaginalis grafts show high technical success (90–100%) with low metabolic demand. More contemporary options, specifically fascia (lata and temporalis) and buccal mucosa grafts (BMG), show superior outcomes. Fascia grafts report technical success rates near 100% with minimal shortening. BMG demonstrates a 94.1% success rate with low de novo ED (0–10%) and rapid tissue integration.
Short Communication
Journal of Urology and Andrology Research, 1(1), 2026, juar002
ABSTRACT:
Retrograde intrarenal surgery (RIRS) is one of the modern minimally invasive endoscopic techniques used in the treatment of nephrolithiasis. The aim of this study was to evaluate the clinical efficacy and postoperative complications of the RIRS procedure.
A total of 50 patients who underwent RIRS were included in the study. The patients were aged between 55 and 65 years. Among them, 28 were males and 22 were females. The average stone size was greater than 1.5 cm, with a density ranging from 1000 to 1200 HU.All procedures were performed under general anesthesia. A flexible ureteroscope and holmium laser were used during surgery. The average operative time ranged from 1.5 to 2 hours.The study demonstrated a 100% stone-free rate. The overall postoperative complication rate was 8%. According to the Traxer (PULS) classification, no ureteral injury (Grade 0) was detected in 98% of cases, while minor Grade 1 ureteral injury was observed in 2% of patients.
The results indicate that RIRS is a highly effective and safe method for the treatment of nephrolithiasis.
A total of 50 patients who underwent RIRS were included in the study. The patients were aged between 55 and 65 years. Among them, 28 were males and 22 were females. The average stone size was greater than 1.5 cm, with a density ranging from 1000 to 1200 HU.All procedures were performed under general anesthesia. A flexible ureteroscope and holmium laser were used during surgery. The average operative time ranged from 1.5 to 2 hours.The study demonstrated a 100% stone-free rate. The overall postoperative complication rate was 8%. According to the Traxer (PULS) classification, no ureteral injury (Grade 0) was detected in 98% of cases, while minor Grade 1 ureteral injury was observed in 2% of patients.
The results indicate that RIRS is a highly effective and safe method for the treatment of nephrolithiasis.
Original Article
Journal of Urology and Andrology Research, 1(1), 2026, juar003
ABSTRACT:
Fournier’s gangrene is an acute necrotizing infection that predominantly affects the subcutaneous adipose tissue of the perianal region and external genitalia. It was first described in 1883 by Jean-Alfred Fournier [1].
Although rare, Fournier’s gangrene represents a serious medical, social, and economic challenge. Its relevance is underscored by the steadily increasing incidence, delayed diagnosis, prolonged hospitalization, high treatment and rehabilitation costs, as well as significant rates of disability and mortality.
The condition most commonly occurs in men of reproductive age with underlying immunodeficiency. More frequently, however, it affects middle-aged and elderly patients with compromised immunity, particularly those with diabetes mellitus, obesity, or chronic alcoholism [2–4]. Nevertheless, cases in women and children have also been reported [4]. Additional predisposing factors include increased scrotal skin moisture, anatomical characteristics of the genital region, and the close proximity of the anal and urethral canals, which create favorable conditions for the proliferation of pathogenic flora [5–7].
In the study by Timerbulatov V. M. et al., the incidence of Fournier’s gangrene has tripled over the past decades [8]. According to epidemiological data, the condition occurs at a frequency of approximately 1.6 cases per 100,000 patients per year [8]. The mean age of patients diagnosed with Fournier’s gangrene is 50.9 years [9, 10]. The disease does not demonstrate seasonal variability [11].
Epidemiological observations indicate a higher incidence in African and Asian countries. However, mortality rates in Europe and the Americas surpass those reported in less developed regions. This discrepancy is most likely associated with the predominance of antibiotic-resistant strains among patients with Fournier’s gangrene [12–14].
Although rare, Fournier’s gangrene represents a serious medical, social, and economic challenge. Its relevance is underscored by the steadily increasing incidence, delayed diagnosis, prolonged hospitalization, high treatment and rehabilitation costs, as well as significant rates of disability and mortality.
The condition most commonly occurs in men of reproductive age with underlying immunodeficiency. More frequently, however, it affects middle-aged and elderly patients with compromised immunity, particularly those with diabetes mellitus, obesity, or chronic alcoholism [2–4]. Nevertheless, cases in women and children have also been reported [4]. Additional predisposing factors include increased scrotal skin moisture, anatomical characteristics of the genital region, and the close proximity of the anal and urethral canals, which create favorable conditions for the proliferation of pathogenic flora [5–7].
In the study by Timerbulatov V. M. et al., the incidence of Fournier’s gangrene has tripled over the past decades [8]. According to epidemiological data, the condition occurs at a frequency of approximately 1.6 cases per 100,000 patients per year [8]. The mean age of patients diagnosed with Fournier’s gangrene is 50.9 years [9, 10]. The disease does not demonstrate seasonal variability [11].
Epidemiological observations indicate a higher incidence in African and Asian countries. However, mortality rates in Europe and the Americas surpass those reported in less developed regions. This discrepancy is most likely associated with the predominance of antibiotic-resistant strains among patients with Fournier’s gangrene [12–14].